EGFR and neoplasm: While the expression of ErbB members in healthy cells, such as fibroblasts and epithelial cells, should prevent the systemic administration of panErbB CAR-T cells in human subjects, the therapeutic efficacy associated to the intratumoral administration of these cells may be benefited from their interaction with cells of the tumor microenvironment, such as the CAFs (see Figure S5).64